NDAORALTABLET
Approved
Feb 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
LOESTRIN 24 FE (ethinyl estradiol; norethindrone acetate) by Teva. Approved for pregnancy. First approved in 2006.
Drug data last refreshed 4d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LOESTRIN 24 FE is an oral contraceptive combining ethinyl estradiol and norethindrone acetate, indicated for pregnancy prevention. The product uses a 24-day active hormone regimen followed by 4 inert tablets, designed to reduce hormone-free interval duration. It works by suppressing ovulation through estrogen and progestin receptor agonism.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), signaling likely team rightsizing and shift from growth to defensive positioning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Career Relevance
Working on LOESTRIN 24 FE offers limited career growth opportunity due to LOE-approaching status and generic competition from MINASTRIN 24 FE. Roles available focus on defensive strategies, cost management, and patient retention rather than expansion or innovation.
Brand Manager
Worked on LOESTRIN 24 FE at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.